http://www.ncbi.nlm.nih.gov/pubmed/23081985

Jpn J Clin Oncol. 2012 Oct 17. [Epub ahead of print]

Gender Difference in Hematological Toxicity Among Lung Cancer Patients Receiving Amrubicin Monotherapy.

Makihara RA, Makino Y, Yamamoto N, Yokote N, Nokihara H, Sekine I, Ohe Y, Tamura T, Yamamoto H.

Source

1Division of Pharmacy, National Cancer Center Hospital.

Abstract

BACKGROUND:

Severe hematological toxicity has been frequently observed during amrubicin monotherapy for patients with lung cancer despite the favorable anti-tumor response. The purpose of this retrospective study was to identify pretreatment factors associated with severe hematological toxicity.

METHODS:

The medical records of lung cancer patients treated with amrubicin monotherapy were reviewed, and univariate and multivariate analyses were conducted.

RESULTS:

From January 2003 to December 2006, the medical records of 103 patients were extracted. Grade 4 neutropenia was frequently observed in females (male, 66% and female, 90%, P = 0.036 in a univariate analysis). In a multivariate analysis, female gender (P = 0.019), body weight loss (P = 0.021) and amrubicin dose (P = 0.028) were significantly correlated with Grade 4 neutropenia.

CONCLUSION:

Gender could be considered as one of the important predictive factors associated with Grade 4 neutropenia in patients receiving amrubicin monotherapy.